ICMJE DISCLOSURE FORM

Date: __ July 21, 2020________

Your Name: ___________ Zan Zhang________

Manuscript Title: __Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma________

Manuscript number (if known): __________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 1 | **All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)**  
   **No time limit for this item.** | **This work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002);**  
   **Time frame: Since the initial planning of the work** |
|   | **This work was supported by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)** |   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | **None**  
   **Time frame: past 36 months** |
| 3 | Royalties or licenses | **None**  
   **Time frame: past 36 months** |
| 4 | Consulting fees | **None**  
   **Time frame: past 36 months** |
|   |                                                                 |       |
|---|-----------------------------------------------------------------|-------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None  |
| 6 | Payment for expert testimony                                    | None  |
| 7 | Support for attending meetings and/or travel                     | None  |
| 8 | Patents planned, issued or pending                               | None  |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None  |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None  |
|11 | Stock or stock options                                          | None  |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None  |
|13 | Other financial or non-financial interests                       | None  |

Please summarize the above conflict of interest in the following box:

The author reported that this work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __ July 21, 2020__
Your Name: __________ Xueyang Xiong __
Manuscript Title: __Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma__
Manuscript number (if known): __________________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | This work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); This work was supported by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | __None

|   | Time frame: past 36 months |
|---|-----------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | __None |
| 3 | Royalties or licenses | __None |
| 4 | Consulting fees | __None |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please summarize the above conflict of interest in the following box:

The author reported that this work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __ July 21, 2020 __________________________________________________________________________
Your Name: __ Rufeng Zhang __________________________________________________________________________
Manuscript Title: __ Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma __________________________________________________________________________
Manuscript number (if known): __________________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| 1 | **Time frame: Since the initial planning of the work** |                                                                                  |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | This work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); This work was supported by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ____None |
| 3 | Royalties or licenses | ____None |
| 4 | Consulting fees | ____None |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please summarize the above conflict of interest in the following box:

The author reported that this work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __ July 21, 2020__

Your Name: __________ Guoliang Xiong ____________________________________________________________________________

Manuscript Title: __Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma__

Manuscript number (if known): ____________________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | This work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); This work was supported by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516) |
| **Time frame: past 36 months** | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ____None |
| 3 | Royalties or licenses | ____None |
| 4 | Consulting fees | ____None |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please summarize the above conflict of interest in the following box:

The author reported that this work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an “X” next to the following statement to indicate your agreement:

**X** I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___________ July 21, 2020 _____________

Your Name: ___________ Changyuan Yu _____________

Manuscript Title: ___________ Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma _____________

Manuscript number (if known): ________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|----------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br>No time limit for this item. | This work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002);<br>This work was supported by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).<br>No time limit for this item. | ___________ None _____________ |
| 3 | Royalties or licenses | ___________ None _____________ |
| 4 | Consulting fees | ___________ None _____________ |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please summarize the above conflict of interest in the following box:

The author reported that this work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __ July 21, 2020

Your Name: __ Lida Xu __

Manuscript Title: __ Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma __

Manuscript number (if known): __

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | This work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); This work was supported by the Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516) |
| **Time frame: past 36 months** | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ____None |
| 3 | Royalties or licenses | ____None |
| 4 | Consulting fees | ____None |
|   |                                                                                           | None                  |
|---|------------------------------------------------------------------------------------------|-----------------------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None                  |
| 6 | Payment for expert testimony                                                              | None                  |
| 7 | Support for attending meetings and/or travel                                              | None                  |
| 8 | Patents planned, issued or pending                                                         | None                  |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                          | None                  |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None                  |
|11 | Stock or stock options                                                                     | None                  |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services           | None                  |
|13 | Other financial or non-financial interests                                                 | None                  |

Please summarize the above conflict of interest in the following box:

The author reported that this work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan Period (2019ZX09721001-007-002); Shenzhen Science and Technology Project (Project number: JCYJ20180507183842516)

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.